Evaluating the claim of enhanced persistence: The case of osteoporosis and implications for payers

Medical Decision Making

Volumn 29, Issue 6, 2009, Pages 690-706

  Kelton, Christina M L ^a   Pasquale, Margaret K ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b P and G Pharmaceuticals Inc   (United States)

Author keywords

Bisphosphonates; Cost effectiveness analysis; Efficacy; Osteoporosis; Persistence; Vertebral and nonvertebral fractures.

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; CALIBRATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FRAGILITY FRACTURE; GROUPS BY AGE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PROBABILITY; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; VALIDATION STUDY; VERTEBRA FRACTURE;

AGED; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COST OF ILLNESS; DIPHOSPHONATES; HUMANS; MARKOV CHAINS; MIDDLE AGED; OSTEOPOROSIS; QUALITY-ADJUSTED LIFE YEARS;

EID: 72149129772     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X09336143     Document Type: Article

References (51)

1. National Osteoporosis Foundation. Disease statistics. Available from: http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed 13 August 2007.
2. Fleurence RL, Iglesias CP, Johnson JM The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics. 2007 ; 25: 913-933.
3. Zethraeus N., Borgström F., Ström O., Kanis JA, Jönsson B. Cost-effectiveness of the treatment and prevention of osteoporosis: a review of the literature and a reference model. Osteoporos Int. 2007 ; 18: 9-23.
4. Tosteson Ana, Melton LJ Dawson-Hughes B., et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008 ; 19: 437-447.
5. Cramer JA, Gold DT, Silverman SL, Lewiecki EM A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007 ; 18: 1023-1031.
6. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int. 2006 ; 17: 1638-1644.
7. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006 ; 17: 922-928.
8. Data on file, Procter & Gamble Pharmaceuticals, Inc., 2006.
9. Mullins CD, Ohsfeldt RL Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm. 2003 ; 9: 150-8.10.
10. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006 ; 81: 1013-1022.
11. Weycker D., Macarios D., Edelsberg J., Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007 ; 18: 271-277.
12. Curtis JR, Westfall AO, Cheng H., Lyles K., Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008 ; 23: 1435-1441.
13. Gallagher AM, Rietbrock S., Olson M., van Staa TP Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008 ; 23: 1569-1575.
14. Cotté F-E., Fautrel B., De Pouvourville G. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med Decis Making. 2009 ; 29: 129-139.
15. Braun S. Application of computer-algebra simulation (CALS) in industry. Math Comput Simulation. 2000 ; 53: 249-257.
16. Adachi JD, Magowan SH, Lange JL, Gehlbach SH Three-fourths of fragility fractures are nonvertebral among women in managed care [abstract]. Calcif Tissue Int. 2006 ; 78 (suppl 1). S124.
17. Adachi JD, Magowan SH, Borisova NN, Lange JL, Ohsfeldt RL Greater than 90% of managed care cost for fragility fractures is nonvertebral in nature among women [abstract]. Calcif Tissue Int. 2006 ; 78 (suppl 1). S125.
18. Kanis JA, Johnell O., Oden A., et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004 ; 15: 20-26.
19. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000 ; 85: 4118-4124.
20. Chesnut CH III, Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 ; 19: 1241-1249.
21. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999 ; 282: 1344-1352.
22. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004 ; 74: 129-135.
23. Ingenix Lab/Rx Database and Marketscan Commercial Claims and Encounters and Medicare Supplemental and Coordinator of Benefits databases, 2000-2007.
24. Tosteson Ana, Jönsson B., Grima DT, OBrien BJ, Black DM, Adachi JD Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int. 2001 ; 12: 849-857.
25. Huybrechts KF, Ishak KJ, Caro JJ Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006 ; 38: 922-928.
26. Roux C., Seeman E., Eastell R., et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin. 2004 ; 20: 433-439.
27. Burge RT, King AB, Balda E., Worley D. Methodology for estimating current and future burden of osteoporosis in state populations: application to Florida in 2000 through 2025. Value Health. 2003 ; 6: 574-583.
28. Melton LJ III, Crowson CS, OFallon WM Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int. 1999 ; 9: 29-37.
29. Melton LJ III, Lane AW, Cooper C., Eastell R., OFallon WM, Riggs BL Prevalence and incidence of vertebral deformities. Osteoporos Int. 1993 ; 3: 113-119.
30. Black DM, Palermo L., Grima DT Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fracture. Value Health. 2006 ; 9: 54-58.
31. National Osteoporosis Foundation. Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int. 1998 ; 8 (suppl 4). S1-88.
32. IMS Health. IMS National Prescription Audit, available by subscription. Accessed 9 April 2008.
33. Simon J., Borisov NN, Sheer RL, Steinbuch M. Clinical vertebral fracture outcomes: medical resource utilization and costs in the first year following the fracture [abstract]. J Bone Miner Res. 2005 ; 20 (suppl 1). S157.
34. Ohsfeldt RL, Borisov NN, Sheer RL Fragility fracture-related direct medical costs in the first year following a nonvertebral fracture in a managed care setting. Osteoporos Int. 2006 ; 17: 252-258. 35. Bureau of Labor Statistics, US Department of Labor. Available from: http://www.bls.gov. Accessed 9 April 2008.
35. Lindsay R., Silverman SL, Cooper C., et al. Risk of new vertebral fractures in the year following a fracture. JAMA. 2001 ; 285: 320-323.
36. Wolters Kluwer Health. Medi-Span Price Rx. Available by subscription from URL: http://www.medispan.com/marketing/. Accessed 9 April 2008.
37. Hanmer J., Lawrence WF, Anderson JP, Kaplan RM, Fryback DG Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006 ; 26: 391-400.
38. Ström O., Borgström F., Kanis JA, et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int. 2009 ; 20: 23-34.
39. Earnshaw SR, Graham CN, Ettinger B., Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007 ; 23: 2517-2529.
40. Dusing ML, Guo JJ, Kelton CML, Pasquale MK Competition and price discounts for a hospital buyer in the anti-infective pharmaceutical market. J Pharm Fin Econ Pol. 2005 ; 14: 59-85.
41. Guo JJ, Kelton CML Competition: brand-name versus generic drugs. In: Fulda TR, Wertheimer AI, eds. Handbook of Pharmaceutical Public Policy. New York: Haworth ; 2007. p 395-416.
42. Guo JJ, Kelton CML, Pasquale MK, et al. Price and market-share competition of firms selling anti-ulcer gastric medications in the Ohio Medicaid market. Int J Pharm Med. 2004 ; 18: 271-282.
43. Jing Y., Kelton CML, Guo JJ, et al. Price, utilization, and spending for antipsychotic medications in the Medicaid program. Drug Benefit Trends. 2007 ; 19: 27-41.
44. Jing Y., Klein P., Kelton CML, Li X., Guo JJ Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005. AIDS Res Ther. 2007 ; 4: 22.
45. Russell RGG Determinants of structure-function relationships among bisphosphonates. Bone. 2007 ; 40 (suppl 2). S21-5.
46. Hughes D., Cowell W., Koncz T., Cramer J. Methods for integrating medication compliance and persistence in pharmacoeconomics evaluations. ISPOR Medication Compliance and Persistence Special Interest Group, Economics of Medication Compliance Working Group. Value Health. 2007 ; 10: 498-509.
47. Burge RT, Dawson-Hughes B., Solomon DH, Wong JB, King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007 ; 22: 465-475.
48. Grima DT, Papaioannou A., Thompson MF, Pasquale MK, Adachi JD Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int. 2008 ; 19: 687-697.
49. Brecht JG, Kruse HP, Möhrke W., Oestreich A., Huppertz E. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharm Res. 2004 ; 24: 1-10.
50. Grima DT, Burge RT, Becker DL, Tosteson Ana. Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T. 2002 ; 27: 448-455.
51. Borgström F., Carlsson Å, Sintonen H., et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int. 2006 ; 17: 996-1007.